MeSH D000081207 - primary immunodeficiency diseases
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
D000081207:
Primary immunodeficiency diseases
D000081208:Hereditary complement deficiency diseases
0 Companies
0 Drugs
Success rate
D001260:Ataxia telangiectasia
0 Companies
0 Drugs
Success rate
D001816:Bloom syndrome
0 Companies
0 Drugs
Success rate
D002609:Chediak-higashi syndrome
0 Companies
0 Drugs
Success rate
D007589:Job syndrome
0 Companies
0 Drugs
Success rate
D014923:Wiskott-aldrich syndrome
0 Companies
0 Drugs
Success rate
D018370:Leukocyte-adhesion deficiency syndrome
0 Companies
0 Drugs
Success rate
D053306:Hyper-igm immunodeficiency syndrome
0 Companies
0 Drugs
Success rate
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Pharming | Leniolisib | Joenja | 2032-02-19 | 2023-03-24 |
Clinical Trials
Historical Success Rate
Phase 1
100%9/9
Phase 2
16%3/19
Phase 3
0%0/3
Approved: 0Overall Success rate: 0%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use